人类白血病免疫治疗的主要依据,是最近十几年所进行的动物免疫治疗实验研究的结果。许多作者认为免疫预防和免疫治疗对动物白血病是有效的,可预防或推迟白血病的发生,降低发病率和延长生存期。Mathe等在L_(1210)白血病证明BCG与用化学方法异构或用放射线照射过的白血病细胞进行主动特异性免疫治疗可使部分动物痊愈。Caridinali报导用短小棒状杆菌进行免疫治疗,延长了白血病动物的生存期。迄今文献上已见到不少有关人类白血病的免疫治疗的研究报导,与同期对照研究相比,虽有一些结果认为免疫治疗无效,但大 The main basis of immunotherapy for human leukemia is the result of experimental studies on animal immunotherapy conducted in the last decade or more. Many authors believe that immunoprophylaxis and immunotherapy are effective against animal leukemia, preventing or delaying the onset of leukemia, reducing the incidence and prolonging survival. Mathe et al. in L_(1210) leukemia demonstrated that BCG could be cured in some animals by active specific immunotherapy with chemically heterogeneous or irradiated leukemia cells. Caridinali reported that immunotherapy with Corynebacterium parvum has prolonged the survival of leukemia animals. Up to now, there have been many reports in the literature on immunotherapy for human leukemia. Compared with the same-period control study, although some results suggest that immunotherapy is ineffective,